Global Opioid Induced Constipation Market Size

Opioid Induced Constipation (OIC) Market Analysis

Opioid-Induced Constipation (OIC) market studied was anticipated to grow with a CAGR of nearly 4.5% during the forecast period, 2022-2027.

Opioid use at high doses and for long periods can impair immune system function, complicating the course of COVID-19 disease. In various stages of COVID-19, potential suppression of parts of the immune response may be important in prevention, clinical support, and therapeutic use of medications. Additionally, as per the World Health Organization update of August 2021, During the COVID-19 pandemic, there are a substantial increase in drug overdose deaths reported in the USA, primarily driven by rapid increases in overdose deaths involving synthetic opioids Because of such instances, the federal government has taken initiatives to careful usage of opioids drugs and side effects associated with it, which can later impact the growth of the studied market.

The major factor attributing to the growth of the market is an increasing number of geriatric patients as these patients use opioid analgesics such as morphine, hydromorphone, codeine, etc. as a prescription for chronic non-cancer pain which has severe adverse effects on the digestive system resulting in huge demand for OIC drugs. For instance, according to the Center for Diseases Control and Prevention November 2021, the number of OIC prescriptions increased by 153,260,450 in 2019 and 142,816,781 in 2020. Thus, the rising volume of patient pool with opioid users demands efficient medication for OIC ailments which is likely to fuel the Opioid-Induced Constipation market over the forecast period.

The geriatric population is expected to have a significant impact on the market studied as people aged above 65 are more prone to chronic diseases. According to the World Health Organization Facts 2021, by 2030, 1 out of every 6 people on the planet will be 60 years old or older. The number of people aged 60 and up is expected to rise from 1 billion in 2020 to 1.4 billion by 2050. By 2050, the global population of people aged 60 and above will get double to reach 2.1 billion. Between 2020 and 2050, the number of people aged 80 and above is expected to triple, reaching 426 million. Thus, the increasing use of opioid analgesic prescriptions along with the growing geriatric population in developed nations boosted the market over the forecast period.

However, lack of awareness about OIC among the patients considering it as a syndrome resulting in a preference for general laxatives and ongoing research activities to develop next-generation analgesics to replace opioids are likely to hamper the market growth. In contrast, the rise in the global geriatric population preferring OIC drugs for efficient, rapid relief and awareness among the developed nations is expected to boost the growth of the market.